WANG Wan’e, ZHU Changquan, LI Jing, et al. Clinical Research on Huazhuo Kangxian Baogan Decoction in the Treatment of Chronic Hepatitis B Liver Fibrosis[J]. 2020,20(10):1189-1192.
WANG Wan’e, ZHU Changquan, LI Jing, et al. Clinical Research on Huazhuo Kangxian Baogan Decoction in the Treatment of Chronic Hepatitis B Liver Fibrosis[J]. 2020,20(10):1189-1192. DOI: 10.14009/j.issn.1672-2124.2020.10.010.
OBJECTIVE: To probe into the clinical effect of Huazhuo Kangxian Baogan decoction in the treatment of chronic hepatitis B( CHB) liver fibrosis. METHODS: Totally 108 patients with CHB liver fibrosis admitted to the Fourth People’s Hospital of Huai’an from Sept. 2018 to Sept. 2019 were selected and divided into control group( 54 cases
treated with recombinant human interferon α2 b) and research group( 54 cases
given Huazhuo Kangxian Baogan decoction combined with recombinant human interferon α2 b) via random number table
both groups were treated for 3 months. Differences in clinical efficacy
liver function indicator
liver fibrosis indicator
histological score
immune function indicator and incidences of adverse drug reactions were compared between two groups. RESULTS: The clinical total effective rate of research group was 88. 89%( 48/54)
which was significantly higher than that of the control group( 74. 07%
40/54)
with statistically significant difference( P <0. 05). After treatment
the aspartate aminotransferase
alanine aminotransferase
total bilirubin
laminin
hyaluronic acid and type-Ⅳ collagen levels of research group were significantly lower than those of the control group; the degree of liver fibrosis and score of inflammation activity of research group were significantly lower than those of the control group; the CD8+of research group was significantly lower than that of the control group
while the nature killer cell
CD4+and CD4+/CD8 levels were significantly higher than those of the control group
with statistically significant differences( P < 0. 05). During treatment
the incidences of adverse drug reactions of control group and research group were respectively 14. 81%( 8/54) and 9. 26%( 5/54)
the difference had no statistical significance( χ2= 0. 787
P = 0. 375). CONCLUSIONS: Huazhuo Kangxian Baogan decoction has good clinical efficacy in the treatment of CHB liver fibrosis
which can improve liver function and severity of fibrosis
reduce liver inflammation
promote immune function
with high safety.
关键词
慢性乙型肝炎肝纤维化化浊抗纤保肝汤临床研究
Keywords
Chronic hepatitis BLiver fibrosisHuazhuo Kangxian Baogan decoctionClinical study